(VIANEWS) – Cameco Corporation (CCJ), Palomar Holdings (PLMR), Astrazeneca (AZN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Cameco Corporation (CCJ)
25.9% sales growth and 4.23% return on equity
Cameco Corporation produces and sells uranium. It operates in two segments, Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, and milling, as well as purchase and sale of uranium concentrate. The Fuel Services segment engages in the refining, conversion, and fabrication of uranium concentrate, as well as the purchase and sale of conversion services. This segment also produces fuel bundles or reactor components for CANDU reactors. The company sells its uranium and fuel services to nuclear utilities in the Americas, Europe, and Asia. Cameco Corporation was incorporated in 1987 and is headquartered in Saskatoon, Canada.
Earnings Per Share
As for profitability, Cameco Corporation has a trailing twelve months EPS of $0.43.
PE Ratio
Cameco Corporation has a trailing twelve months price to earnings ratio of 99.09. Meaning, the purchaser of the share is investing $99.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.23%.
Sales Growth
Cameco Corporation’s sales growth for the next quarter is 25.9%.
Volume
Today’s last reported volume for Cameco Corporation is 7495390 which is 106.53% above its average volume of 3629040.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Nov 29, 2023, the estimated forward annual dividend rate is 0.09 and the estimated forward annual dividend yield is 0.21%.
2. Palomar Holdings (PLMR)
21.9% sales growth and 20.38% return on equity
Palomar Holdings, Inc., an insurance holding company, provides specialty property insurance to residential and commercial customers. The company offers personal and commercial specialty property insurance products, including residential and commercial earthquake, commercial all risk, specialty homeowners, inland marine, Hawaii hurricane, and residential flood, as well as other products, such as assumed reinsurance, commercial flood, real estate error and omission, and real estate investor products. It markets and distributes its products through retail agents, wholesale brokers, program administrators, and carrier partnerships. The company was formerly known as GC Palomar Holdings. Palomar Holdings, Inc. was incorporated in 2013 and is headquartered in La Jolla, California.
Earnings Per Share
As for profitability, Palomar Holdings has a trailing twelve months EPS of $3.8.
PE Ratio
Palomar Holdings has a trailing twelve months price to earnings ratio of 24.82. Meaning, the purchaser of the share is investing $24.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.38%.
Moving Average
Palomar Holdings’s value is above its 50-day moving average of $87.03 and way higher than its 200-day moving average of $74.60.
Sales Growth
Palomar Holdings’s sales growth for the next quarter is 21.9%.
Volume
Today’s last reported volume for Palomar Holdings is 93551 which is 47.07% below its average volume of 176751.
3. Astrazeneca (AZN)
13.9% sales growth and 16.74% return on equity
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and BenevolentAI for drug discovery for systemic lupus erythematosus. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Earnings Per Share
As for profitability, Astrazeneca has a trailing twelve months EPS of $1.9.
PE Ratio
Astrazeneca has a trailing twelve months price to earnings ratio of 36.28. Meaning, the purchaser of the share is investing $36.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.74%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 9, 2024, the estimated forward annual dividend rate is 1.49 and the estimated forward annual dividend yield is 1.69%.
4. Chubb Corporation (CB)
7% sales growth and 16.76% return on equity
Chubb Limited provides insurance and reinsurance products worldwide. The company's North America Commercial P&C Insurance segment offers commercial property, casualty, workers' compensation, package policies, risk management, financial lines, marine, construction, environmental, medical risk, cyber risk, surety, and casualty; and group accident and health insurance to large, middle market, and small commercial businesses. Its North America Personal P&C Insurance segment provides affluent and high net worth individuals and families with homeowners, automobile and collector cars, valuable articles, personal and excess liability, travel insurance, and recreational marine insurance and services. The company's North America Agricultural Insurance segment offers multiple peril crop and crop-hail insurance; and coverage for farm, ranch, and specialty property and casualty, and commercial agriculture products. Its Overseas General Insurance segment provides coverage for traditional commercial property and casualty; specialty categories, such as financial lines, marine, energy, aviation, political risk, and construction; and group accident and health, and traditional and specialty personal lines for corporations, middle markets, and small customers through retail brokers, agents, and other channels. The company's Global Reinsurance segment offers traditional and specialty reinsurance under the Chubb Tempest Re brand to property and casualty companies. Its Life Insurance segment provides protection and savings products comprising whole life, endowment plans, individual and life, group term life, health protection, personal accident, credit life, universal life, group employee benefits, and unit linked contracts. It markets its products primarily through insurance and reinsurance brokers. The company was formerly known as ACE Limited and changed its name to Chubb Limited in January 2016. Chubb Limited was incorporated in 1985 and is headquartered in Zurich, Switzerland.
Earnings Per Share
As for profitability, Chubb Corporation has a trailing twelve months EPS of $21.81.
PE Ratio
Chubb Corporation has a trailing twelve months price to earnings ratio of 11.27. Meaning, the purchaser of the share is investing $11.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.76%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Sep 13, 2024, the estimated forward annual dividend rate is 3.64 and the estimated forward annual dividend yield is 1.28%.
Volume
Today’s last reported volume for Chubb Corporation is 1196190 which is 31.43% below its average volume of 1744700.
